Teijin, Teijin Regenet and Shinshu University Hospital strengthen CAR-T manufacturing in Japan
- Three parties signed a joint research agreement to develop manufacturing technologies for cell and gene therapies, including CAR-T.
- Shinshu University Hospital contributes CAR-T research, development and clinical expertise; Teijin Regenet provides CDMO manufacturing and quality‑management know‑how.
- The Cell Processing Center at Shinshu University Hospital will be used to explore manufacturing automation and efficiency improvements.
- Partners will accumulate practical knowledge on quality testing technologies and quality‑control methodologies to strengthen Japan's manufacturing base.
Partnership
Teijin Limited, Teijin Regenet and Shinshu University Hospital entered a joint research agreement to develop manufacturing technologies for cell and gene therapy products, including chimeric antigen receptor T‑cell (CAR‑T) therapies.
Technical focus
The collaboration combines Shinshu University Hospital's CAR‑T research, development and clinical application expertise with Teijin Regenet's contract development and manufacturing organization (CDMO) experience in manufacturing and quality management for regenerative medicine products.
Facilities and methods
The partners will use the Cell Processing Center (CPC) at Shinshu University Hospital to investigate automation and efficiency improvements in manufacturing and to accumulate practical knowledge on quality testing technologies and quality‑control methodologies.
Objective
The project aims to advance manufacturing technologies and strengthen Japan's infrastructure and personnel capacity for cell and gene therapies, with the goal of contributing to wider availability and patient access to these treatments.
Source: Teijin
